EP2365065A3 - Variantes de l'endonucléase homing I-CreI à nouvelle spécificité de clivage et leur utilisation - Google Patents

Variantes de l'endonucléase homing I-CreI à nouvelle spécificité de clivage et leur utilisation Download PDF

Info

Publication number
EP2365065A3
EP2365065A3 EP10012255A EP10012255A EP2365065A3 EP 2365065 A3 EP2365065 A3 EP 2365065A3 EP 10012255 A EP10012255 A EP 10012255A EP 10012255 A EP10012255 A EP 10012255A EP 2365065 A3 EP2365065 A3 EP 2365065A3
Authority
EP
European Patent Office
Prior art keywords
homing endonuclease
cre
cleavage specificity
endonuclease variants
novel cleavage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10012255A
Other languages
German (de)
English (en)
Other versions
EP2365065A2 (fr
EP2365065A8 (fr
Inventor
Frédéric PAQUES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellectis SA
Original Assignee
Cellectis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36177968&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2365065(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cellectis SA filed Critical Cellectis SA
Publication of EP2365065A2 publication Critical patent/EP2365065A2/fr
Publication of EP2365065A8 publication Critical patent/EP2365065A8/fr
Publication of EP2365065A3 publication Critical patent/EP2365065A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
EP10012255A 2005-10-25 2006-10-03 Variantes de l'endonucléase homing I-CreI à nouvelle spécificité de clivage et leur utilisation Withdrawn EP2365065A3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2005/003564 WO2007060495A1 (fr) 2005-10-25 2005-10-25 Variants de l'endonuclease homing i-crei a nouvelle specificite de clivage et leur utilisation
EP06842325.0A EP1954807B2 (fr) 2005-10-25 2006-10-03 Variants de l'endonuclease homing i-crei a nouvelle specificite de clivage et leur utilisation

Related Parent Applications (5)

Application Number Title Priority Date Filing Date
EP06842325.0 Division 2006-10-03
WOPCT/IB20/06003883 Previously-Filed-Application 2006-10-03
WOPCT/IB0003/883 Previously-Filed-Application 2006-10-03
EP06842325.0A Division-Into EP1954807B2 (fr) 2005-10-25 2006-10-03 Variants de l'endonuclease homing i-crei a nouvelle specificite de clivage et leur utilisation
WOPCT/IB2006/003883 Previously-Filed-Application 2006-10-03

Publications (3)

Publication Number Publication Date
EP2365065A2 EP2365065A2 (fr) 2011-09-14
EP2365065A8 EP2365065A8 (fr) 2011-11-23
EP2365065A3 true EP2365065A3 (fr) 2012-10-10

Family

ID=36177968

Family Applications (4)

Application Number Title Priority Date Filing Date
EP06842325.0A Active EP1954807B2 (fr) 2005-10-25 2006-10-03 Variants de l'endonuclease homing i-crei a nouvelle specificite de clivage et leur utilisation
EP10012256A Withdrawn EP2368979A3 (fr) 2005-10-25 2006-10-03 Variantes de l'endonucléase homing I-CreI à nouvelle spécificité de clivage et leur utilisation
EP10012255A Withdrawn EP2365065A3 (fr) 2005-10-25 2006-10-03 Variantes de l'endonucléase homing I-CreI à nouvelle spécificité de clivage et leur utilisation
EP10012257A Withdrawn EP2368980A3 (fr) 2005-10-25 2006-10-03 Variantes de l'endonucléase homing I-CreI à nouvelle spécificité de clivage et leur utilisation

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP06842325.0A Active EP1954807B2 (fr) 2005-10-25 2006-10-03 Variants de l'endonuclease homing i-crei a nouvelle specificite de clivage et leur utilisation
EP10012256A Withdrawn EP2368979A3 (fr) 2005-10-25 2006-10-03 Variantes de l'endonucléase homing I-CreI à nouvelle spécificité de clivage et leur utilisation

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP10012257A Withdrawn EP2368980A3 (fr) 2005-10-25 2006-10-03 Variantes de l'endonucléase homing I-CreI à nouvelle spécificité de clivage et leur utilisation

Country Status (9)

Country Link
US (2) US20110191870A1 (fr)
EP (4) EP1954807B2 (fr)
JP (1) JP2009513129A (fr)
CN (1) CN101297032B (fr)
AU (1) AU2006307603B2 (fr)
CA (1) CA2625979A1 (fr)
DK (1) DK1954807T3 (fr)
ES (1) ES2393508T3 (fr)
WO (2) WO2007060495A1 (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009095742A1 (fr) 2008-01-31 2009-08-06 Cellectis Nouvelle méganucléase à chaîne unique dérivée de l'i-crei et ses utilisations
US20060206949A1 (en) 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
ATE466933T1 (de) 2005-03-15 2010-05-15 Cellectis I-crei-meganuklease-varianten mit modifizierter spezifität sowie verfahren zu ihrer herstellung und verwendung
DK3246403T3 (da) 2005-10-18 2020-10-26 Prec Biosciences Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet
KR101703299B1 (ko) * 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
CA2689345C (fr) 2007-06-05 2017-07-11 Bayer Bioscience N.V. Procedes et moyens permettant le remplacement precis d'un adn cible dans des organismes eucaryotes
US20140112904A9 (en) 2007-06-06 2014-04-24 Cellectis Method for enhancing the cleavage activity of i-crei derived meganucleases
WO2008149176A1 (fr) * 2007-06-06 2008-12-11 Cellectis Variants de méganucléase clivant une séquence cible d'adn issue du locus rosa26 de souris et leurs utilisations
WO2009013559A1 (fr) 2007-07-23 2009-01-29 Cellectis Variants de méganucléase clivant une séquence cible d'adn à partir du gène bêta de l'hémoglobine humaine et ses utilisations
WO2009019528A1 (fr) * 2007-08-03 2009-02-12 Cellectis Variants de méganucléases clivant une séquence cible d'adn provenant du gène de la chaine gamma du récepteur d'interleukine-2 humain et ses utilisations
ES2422291T3 (es) 2007-10-31 2013-09-10 Prec Biosciences Inc Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas
WO2009076292A2 (fr) * 2007-12-07 2009-06-18 Precision Biosciences, Inc. Méganucléases conçues rationnellement avec des séquences d'identification trouvées dans des régions hypersensibles à l'adnase du génome humain
WO2009074842A1 (fr) * 2007-12-13 2009-06-18 Cellectis Enzymes chimères améliorées de méganucléase et leurs utilisations
WO2009114321A2 (fr) 2008-03-11 2009-09-17 Precision Biosciencs, Inc. Méganucléases rationnellement conçues pour modification par génie génétique du génome du maïs
JP2011527906A (ja) 2008-07-14 2011-11-10 プレシジョン バイオサイエンシズ，インク． Ｉ−ＣｒｅＩ由来メガヌクレアーゼの認識配列およびその使用
EP2329017A2 (fr) * 2008-08-04 2011-06-08 Cellectis Nouvelle méthode pour générer des méganucléases ayant des caractéristiques modifiées
US9273296B2 (en) * 2008-09-08 2016-03-01 Cellectis Meganuclease variants cleaving a DNA target sequence from a glutamine synthetase gene and uses thereof
EP2180058A1 (fr) 2008-10-23 2010-04-28 Cellectis Système de recombinaison de méganucléase
US12612435B2 (en) 2009-01-12 2026-04-28 Ulla Bonas Modular DNA-binding domains and methods of use
EP2206723A1 (fr) 2009-01-12 2010-07-14 Bonas, Ulla Domaines modulaires de liaison à l'ADN
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
WO2010136981A2 (fr) 2009-05-26 2010-12-02 Cellectis Variants de méganucléase clivant le génome d'un virus non intégratif pathogène et leurs utilisations
WO2011007193A1 (fr) 2009-07-17 2011-01-20 Cellectis Vecteurs viraux codant pour une matrice de réparation d'adn et contenant une méganucléase spécifique de site associée à un virion pour un ciblage de gène
WO2011021062A1 (fr) 2009-08-21 2011-02-24 Cellectis Variants de méganucléase clivant une séquence d’adn cible du gène d’acide lysosomique alpha-glucosidase humain et utilisations de ceux-ci
WO2011036640A2 (fr) * 2009-09-24 2011-03-31 Cellectis Réactifs à base de méganucléase et leurs utilisations pour traiter des maladies génétiques provoquées par des mutations de changement de phase/ non sens
EP2319872A1 (fr) 2009-11-04 2011-05-11 BASF Plant Science GmbH Amidon de type amylopectine avec stabilité de rétrogradation améliorée
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
WO2011101696A1 (fr) 2010-02-18 2011-08-25 Cellectis Système de recombinaison de méganucléase amélioré
EP2563915A1 (fr) * 2010-04-30 2013-03-06 Cellectis Variants de i-crei ayant une nouvelle spécificité et procédés pour leur génération
EP2569424A1 (fr) 2010-05-12 2013-03-20 Cellectis Variants de méganucléase clivant une séquence cible d'adn du gène de dystrophine et leurs utilisations
EP2569435A1 (fr) 2010-05-12 2013-03-20 Cellectis Variants de méganucléase clivant une séquence cible d'adn du gène de la rhodopsine et utilisations correspondantes
AU2011256838B2 (en) 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
AU2011264074B2 (en) 2010-06-09 2015-01-22 Bayer Cropscience Nv Methods and means to modify a plant genome at a nucleotide sequence commonly used in plant genome engineering
MX347575B (es) 2010-06-09 2017-05-03 Bayer Cropscience N V * Metodos y medios para modificar un genoma vegetal en una secuencia de nucleotidos usada comunmente en la ingenieria genetica de genomas vegetales.
CA2802822A1 (fr) 2010-06-15 2012-01-05 Cellectis Procede permettant d'ameliorer le clivage d'un adn par une endonuclease sensible a la methylation
EP2591098A2 (fr) 2010-07-07 2013-05-15 Cellectis Variants de méganucléases coupant une séquence cible d'adn dans le gène nanog et leurs utilisations
WO2012010976A2 (fr) 2010-07-15 2012-01-26 Cellectis Variants de méganucléases clivant une séquence d'adn cible dans le gène tert et leurs utilisations
WO2012007848A2 (fr) 2010-07-16 2012-01-19 Cellectis Variants de méganucléase clivant une séquence d'adn cible dans le gène was et leurs utilisations
SG189482A1 (en) 2010-10-27 2013-05-31 Cellectis Method for increasing the efficiency of double-strand break-induced mutagenesis
US9044492B2 (en) 2011-02-04 2015-06-02 Cellectis Sa Method for modulating the efficiency of double-strand break-induced mutagenesis
US20140115726A1 (en) 2011-04-05 2014-04-24 Cellectis New tale-protein scaffolds and uses thereof
WO2012138901A1 (fr) 2011-04-05 2012-10-11 Cellectis Sa Procédé pour l'amélioration de l'efficacité d'endonucléases à coupure rare et ses utilisations
CA2834375C (fr) 2011-04-27 2020-07-14 Amyris, Inc. Procedes de modification genomique
WO2012158778A1 (fr) 2011-05-16 2012-11-22 Cellectis S.A. Souches d'algues ou de cyanobactéries transgéniques deux fois plus sûres pour empêcher leur implantation et leur dissémination dans des écosystèmes naturels
EP2535416A1 (fr) 2011-05-24 2012-12-19 BASF Plant Science Company GmbH Développement d'une pomme de terre résistante au phytophthora avec rendement amélioré
EP3683319A1 (fr) 2011-06-01 2020-07-22 Precision Biosciences, Inc. Procédés et produits pour la production de lignées cellulaires génétiquement modifiées de mammifère par des transgènes amplifiés
EP2729567B1 (fr) 2011-07-08 2016-10-05 Cellectis Procédé d'amélioration de l'efficacité de mutagenèse induite par une cassure double brin
BR112014003919A2 (pt) 2011-08-22 2017-03-14 Bayer Cropscience Ag métodos e meios para modificar um genoma de planta
US20150225734A1 (en) 2012-06-19 2015-08-13 Regents Of The University Of Minnesota Gene targeting in plants using dna viruses
US20140120578A1 (en) 2012-11-01 2014-05-01 Medicago Inc. Plants for production of therapeutic proteins
ES2778033T3 (es) 2012-11-16 2020-08-07 Poseida Therapeutics Inc Enzimas específicas de sitio y métodos de uso
CN105120656A (zh) 2012-12-21 2015-12-02 塞尔克蒂斯股份有限公司 冷诱导甜味降低的马铃薯
US10113162B2 (en) 2013-03-15 2018-10-30 Cellectis Modifying soybean oil composition through targeted knockout of the FAD2-1A/1B genes
US9476065B2 (en) 2013-12-19 2016-10-25 Amyris, Inc. Methods for genomic integration
US9522936B2 (en) 2014-04-24 2016-12-20 Sangamo Biosciences, Inc. Engineered transcription activator like effector (TALE) proteins
WO2015193858A1 (fr) 2014-06-20 2015-12-23 Cellectis Pommes de terre à teneur réduite en enzyme gbss
JP2018521689A (ja) 2015-06-17 2018-08-09 ポセイダ セラピューティクス， インコーポレイテッド タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法
US10837024B2 (en) 2015-09-17 2020-11-17 Cellectis Modifying messenger RNA stability in plant transformations
ES3039237T3 (en) 2016-02-02 2025-10-20 Cellectis Modifying soybean oil composition through targeted knockout of the fad3a/b/c genes
US11293033B2 (en) 2016-05-18 2022-04-05 Amyris, Inc. Compositions and methods for genomic integration of nucleic acids into exogenous landing pads
WO2018092072A1 (fr) 2016-11-16 2018-05-24 Cellectis Méthodes de modification de la teneur en acides aminés de plantes par décalages du cadre de lecture
CA3060622A1 (fr) 2017-04-25 2018-11-01 Cellectis Luzerne presentant une composition a teneur reduite en lignine
WO2019126578A1 (fr) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Compositions et procédés permettant de diriger des protéines vers des loci spécifiques dans le génome

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067736A2 (fr) * 2003-01-28 2004-08-12 Cellectis Meganuclease sur mesure et son utilisation

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5006333A (en) * 1987-08-03 1991-04-09 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
FR2646438B1 (fr) * 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5843701A (en) * 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US6063630A (en) * 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5436150A (en) * 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US6395959B1 (en) * 1992-05-05 2002-05-28 Institut Pasteur Nucleotide sequence encoding the enzyme I SceI and the use thereof
US5792632A (en) * 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5474896A (en) * 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5801030A (en) * 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US5830729A (en) * 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
US6232112B1 (en) * 1997-11-24 2001-05-15 Flinders Technologies Pty Ltd Of Flinders University Reagents and methods for diversification of DNA
WO2002068471A2 (fr) * 2000-12-21 2002-09-06 Bristol-Myers Squibb Company Molecules d'acide nucleique et polypeptides representant un canal cationique humain
WO2003038444A2 (fr) * 2001-10-31 2003-05-08 Pfizer Products Inc. Biomarqueurs de reponse hepatique
US20100151556A1 (en) * 2002-03-15 2010-06-17 Cellectis Hybrid and single chain meganucleases and use thereof
US8206965B2 (en) 2002-03-15 2012-06-26 Cellectis S.A. Hybrid and single chain meganucleases and use thereof
WO2009095742A1 (fr) * 2008-01-31 2009-08-06 Cellectis Nouvelle méganucléase à chaîne unique dérivée de l'i-crei et ses utilisations
AU2003290518A1 (en) 2002-09-06 2004-04-23 Fred Hutchinson Cancer Research Center Methods and compositions concerning designed highly-specific nucleic acid binding proteins
US7888121B2 (en) * 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
ATE466933T1 (de) † 2005-03-15 2010-05-15 Cellectis I-crei-meganuklease-varianten mit modifizierter spezifität sowie verfahren zu ihrer herstellung und verwendung
DK3246403T3 (da) † 2005-10-18 2020-10-26 Prec Biosciences Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet
WO2007049095A1 (fr) * 2005-10-25 2007-05-03 Cellectis Variants d'endonuclease de liaison a laglidadg comprenant des mutations dans deux sous-domaines fonctionnels et leur utilisation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067736A2 (fr) * 2003-01-28 2004-08-12 Cellectis Meganuclease sur mesure et son utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ROSEN LAURA E ET AL: "Homing endonuclease I-CreI derivatives with novel DNA target specificities", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 34, no. 17, 1 October 2006 (2006-10-01), pages 4791 - 4800, XP002554264, ISSN: 0305-1048, [retrieved on 20060913], DOI: 10.1093/NAR/GKL645 *
SELIGMAN LENNY M ET AL: "Mutations altering the cleavage specificity of a homing endonuclease", NUCLEIC ACIDS RESEARCH, vol. 30, no. 17, 1 September 2002 (2002-09-01), pages 3870 - 3879, XP002282592, ISSN: 0305-1048 *
SUSSMAN DJANGO ET AL: "Isolation and characterization of new homing endonuclease specificities at individual target site positions", JOURNAL OF MOLECULAR BIOLOGY, vol. 342, no. 1, 3 September 2004 (2004-09-03), pages 31 - 41, XP004563015, ISSN: 0022-2836 *

Also Published As

Publication number Publication date
AU2006307603B2 (en) 2012-08-02
WO2007049156A3 (fr) 2008-02-14
CN101297032A (zh) 2008-10-29
EP1954807B1 (fr) 2012-07-04
WO2007060495A1 (fr) 2007-05-31
EP2365065A2 (fr) 2011-09-14
EP1954807A2 (fr) 2008-08-13
CA2625979A1 (fr) 2007-05-03
US20110191870A1 (en) 2011-08-04
JP2009513129A (ja) 2009-04-02
EP2368979A2 (fr) 2011-09-28
DK1954807T3 (da) 2012-10-15
AU2006307603A1 (en) 2007-05-03
CN101297032B (zh) 2014-10-15
US20130209437A1 (en) 2013-08-15
EP2368979A3 (fr) 2012-10-10
EP2368980A2 (fr) 2011-09-28
WO2007049156A2 (fr) 2007-05-03
ES2393508T3 (es) 2012-12-21
EP2368980A3 (fr) 2012-10-10
EP1954807B2 (fr) 2016-01-27
EP2365065A8 (fr) 2011-11-23

Similar Documents

Publication Publication Date Title
EP2365065A8 (fr) Variantes de l'endonucléase homing I-CreI à nouvelle spécificité de clivage et leur utilisation
EP2343369A8 (fr) Variants d'endonucléase laglidadg présentant des mutations dans deux sous-domaines fonctionnels et leur utilisation
WO2003018767A3 (fr) Transdifferenciation et redifferenciation de cellules somatiques et production de cellules pour therapies cellulaires
WO2004044158A3 (fr) Cultures de cellules souches embryonnaires humaines, et compositions et procedes de culture correspondants
EP2264158A3 (fr) Variants d'enzyme lipolytique
BR0308351A (pt) molécula de ácido nucleico isolada, planta transgênica, e, métodos para produzir uma planta transgênica e para selecionar uma planta contendo uma molécula de ácido nucleico
EP2390315A8 (fr) Endonucléases de restriction haute fidélité
BR0311452A (pt) Processos e materiais para a produção de ácido lático em levedura
MX2018015309A (es) Polipeptidos y polinucleotidos aislados utiles para mejorar la eficacia en el uso de nitrogeno, tolerancia al estres abiotico, rendimiento y biomasa en plantas.
WO2006032469A3 (fr) Vegetaux resistant au stress
WO2005104706A3 (fr) Systeme de reacteur a reservoir a agitation
WO2010093966A3 (fr) Génération d'une enzyme de césure de l'adn stimulant la conversion d'un gène spécifique d'un site à partir d'une endonucléase de ciblage
WO2006031424A3 (fr) Souche e. coli mutante avec production accrue d'acide succinique
WO2004067736A3 (fr) Meganuclease sur mesure et son utilisation
WO2005073390A3 (fr) Microorganisme produisant des acides amines l et procede de production de l’acide amine l
UA103335C2 (ru) Способ изготовления добавки для ферментативного расщепления микотоксинов, добавка и ее применение
BRPI0411874A (pt) potencial de staygreen controlado em plantas por gene simples obtido por engenharia genética
EP2631243A3 (fr) Séquences de nucléotides Msca1 influençant la fertilité mâle des plantes et procédé d'utilisation
GB0421598D0 (en) Modification of plant development and morphology
ATE373102T1 (de) Verbessertes in-vitro-synthesesystem
WO2003070873A3 (fr) Procede de culture de micro-organismes et bioreacteur
AU2003247599A1 (en) Methods of modulating cytokinin related processes in a plant using b3 domain proteins
ATE310823T1 (de) Expressionssystem zur produktion von proteinen in pilzen
UA104575C2 (ru) Способ модифицирования замещения 4-о-мелилглюкуроновой кислоты и/или глюкуроновой кислоты ксилана в растении
WO2003072785A3 (fr) Procede de fermentation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1954807

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 9/22 20060101AFI20120903BHEP

17P Request for examination filed

Effective date: 20130409

17Q First examination report despatched

Effective date: 20130507

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20131119